Untitled

Abstract

In situ micronization is a suitable method for the production of micro-sized drugs. This technique can be performed continuously or discontinuously and uses only common technical equipment. Compared to milled products drug properties are optimized as all particle surfaces are naturally grown, the particle size is more uniformly distributed and the powder is less cohesive.

Stabilizing dispersions of hydrophobic drug molecules using cellulose ethers during anti-solvent synthesis of micro-particulates

“…Cellulose ethers with alkyl-substituents such as MC and HPMC are known to interact with the newly formed particles and prevent particle growth. MC and HPMC which contain methoxyl or hydroxypropyl groups are able to adsorb onto hydrophobic solid surfaces, while polar cellulose ether (HEC) were found to be less effective [36,37]. It was observed that the addition Table 3 Zeta potential of FNB and GF particles in different systems.…”

Mixed micelles of amphiphilic drug promethazine hydrochloride and surfactants (conventional and gemini) at 293.15 K to 308.15 K: Composition, interaction and stability of the aggregates

“…An estimated 20-30% of pharmaceutical compounds have poor bioavailability because of their low solubility [2,3]. For lipophilic drugs with high permeabilities through biomembranes, the dissolution rate limits bioavailability [4]. Various approaches to increase drug solubility, such as use of cosolvents, surfactants, liposome formulations or complexing agents [5][6][7][8][9] as well as the formation of emulsions and solid dispersions [10][11][12] have been described in the literature.…”

Dissolution Improvement and the Mechanism of the Improvement from Cocrystallization of Poorly Water-soluble Compounds

“…Recently, the number of poorly water-soluble candidates in pharmaceutical drug discovery has increased (8,9). Formulation technologies such as micronization (10,11), nanomization (11)(12)(13)(14)(15), solid dispersion (16)(17)(18), oil encapsulation (15), and self-emulsified drug delivery systems (15,19,20) improve the bioavailability (BA) of drug candidates with solubility limitations. However, developing a pharmaceutical product using the latest technologies requires time to secure both stability and solubility (21) and selection of a more soluble API form is important.…”